Introduction
============

Neuroblastoma, the most common extracranial solid tumor in childhood, develops from neural crest progenitor cells.[@b1-cmar-10-1807],[@b2-cmar-10-1807] Neuroblastoma accounts for \~7% of all childhood malignancies, yet is responsible for 15% of all pediatric oncology deaths.[@b3-cmar-10-1807]--[@b5-cmar-10-1807] The prognosis of neuroblastoma patients is widely variable. Some patients may spontaneously regress without chemotherapy, while some relapse with therapy-resistant disease.[@b6-cmar-10-1807] Neuroblastoma cases are generally classified into low-, intermediate-, and high-risk groups.[@b7-cmar-10-1807] Among them, high-risk neuroblastoma patients comprise \~50% of all neuroblastoma cases.[@b8-cmar-10-1807] The 5-year survival rates of high-risk neuroblastoma cases seldom exceed 40% despite intensive, multimodal therapy.[@b9-cmar-10-1807] The difficulty in treating these high-risk neuroblastoma cases might be the distant metastasis of tumors to bone marrow.[@b7-cmar-10-1807],[@b10-cmar-10-1807]

The etiology of neuroblastoma has been partly elucidated but remains obscure. Previous studies have indicated that environmental factors may influence risk of neuroblastoma; however, the theory lacks direct evidence.[@b11-cmar-10-1807],[@b12-cmar-10-1807] Growing attention has been directed to genetic and gene--environmental factors as underlying risks of neuroblastoma. Currently, numerous genetic variants have been determined to play critical roles in neuroblastoma carcinogenesis. For example, *PHOX2B*[@b13-cmar-10-1807],[@b14-cmar-10-1807] and *ALK*[@b15-cmar-10-1807],[@b16-cmar-10-1807] gene mutations were found in some neuroblastoma cases. Genome-wide association studies have also identified polymorphisms located in *TP53*, *HACE1*, *BARD1*, *LIN28B*, *LMO1*, and *CASC15* genes associated with neuroblastoma risk.[@b1-cmar-10-1807],[@b17-cmar-10-1807],[@b18-cmar-10-1807]

*MYCN*, a member of the MYC protooncogene family, was first identified in neuroblastoma cell lines.[@b19-cmar-10-1807] *MYCN* is a critical regulator of various cellular processes, including proliferation, differentiation, and apoptosis.[@b20-cmar-10-1807]--[@b23-cmar-10-1807] Moreover, aberration expression of *MYCN* is associated with tumor initiation and progression.[@b24-cmar-10-1807]--[@b26-cmar-10-1807] Amplification of *MYCN* is present in \~20% of neuroblastoma cases.[@b27-cmar-10-1807] *MYCN* is closely associated with aggressive tumor type and poor prognosis.[@b28-cmar-10-1807],[@b29-cmar-10-1807] Therefore, exploring the role of *MYCN* in carcinogenesis remains a research hotspot. However, few studies have been proposed to evaluate the association of *MYCN* gene polymorphisms and neuroblastoma risk. Given the importance of the *MYCN* gene in cancer initiation and development, we intend to explore whether *MYCN* gene polymorphisms could predispose a patient to neuroblastoma risk.

Patients and methods
====================

Participants
------------

A total of 429 neuroblastoma cases and 884 healthy controls from 3 centers were included in this study.[@b30-cmar-10-1807]--[@b32-cmar-10-1807] All of the cases were newly confirmed and histopathologically diagnosed neuroblastoma patients without progressive disease or previous treatments. The controls were age-, gender-, and ethnicity-matched to cases and were randomly recruited from children undergoing routine medical examination at the same hospital during the same period. All of the enrolled subjects were of Chinese Han ethnicity. More specifically, 36 cases and 72 controls were enrolled from The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University ([Table S1](#SD2-cmar-10-1807){ref-type="supplementary-material"}), 275 cases and 531 controls were enrolled from Guangzhou Women and Children's Medical Center, and the remaining 118 cases and 281 controls were recruited from The First Affiliated Hospital of Zhengzhou University. Written informed consent was obtained from all of the participants' parents. Details of the selection process of the included participants were provided in our previous publication.[@b33-cmar-10-1807]--[@b35-cmar-10-1807] The institutional review board of the above-mentioned 3 hospitals approved the study.

Single-nucleotide polymorphism (SNP) selection and genotyping
-------------------------------------------------------------

We chose potentially functional SNPs of interest from the dbSNP database (<http://www.ncbi.nlm.nih.gov/>) based on the following criteria: 1) minor allele frequency \>5% for Chinese Han subjects; 2) potentially functional, such as affecting the binding capacity of transcription factor or microRNA binding sites, or leading to amino acid alterations. We chose 4 potentially functional SNPs in the *MYCN* gene (rs57961569 G\>A, rs9653226 T\>C, rs13034994 A\>G, and rs60226897 G\>A) for analysis. As predicted by SNPinfo (<http://snpinfo.niehs.nih.gov/>), all of them were located in the transcription factor binding sites. Moreover, they all had a minor allele frequency \>5% in Chinese Han subjects. As shown in [Figure S1](#SD1-cmar-10-1807){ref-type="supplementary-material"}, there was no significant linkage disequilibrium (*R*[@b2-cmar-10-1807]\<0.8) among these 4 SNPs (*R*[@b2-cmar-10-1807]=0.220 between rs57961569 and rs9653226; *R*[@b2-cmar-10-1807]=0.185 between rs57961569 and rs13034994; *R*[@b2-cmar-10-1807]=0.103 between rs57961569 and rs60226897; *R*[@b2-cmar-10-1807]=0.348 between rs9653226 and rs13034994; *R*[@b2-cmar-10-1807]=0.161 between rs9653226 and rs60226897; *R*[@b2-cmar-10-1807]=0.500 between rs13034994 and rs6022689). First, the genomic DNA was extracted from the peripheral blood donated by subjects. The *MYCN* gene polymorphisms were detected using TaqMan real-time PCR, as described elsewhere.[@b36-cmar-10-1807]--[@b39-cmar-10-1807] Eight blank wells containing water as negative controls were also placed in each 384-well plate as the means of quality control. In addition, we randomly regenotyped 10% of the samples and got a concordance rate of 100%.

Statistical analysis
--------------------

Testing of Hardy--Weinberg equilibrium for the selected polymorphisms in controls was performed using a goodness-of-fit χ^2^ test. A 2-sided χ^2^ test was used for comparisons of 2 groups in allele frequencies and demographic variables. We evaluated the associations between genotypes and neuroblastoma risk using odds ratios (ORs) and 95% confidence intervals (CIs) calculated from logistic regression analysis. Risk genotypes were rs57961569 GG, rs9653226 CC, rs13034994 GG, and rs60226897 GG; covariates, including age and gender, were used for adjustment. Statistical analysis was performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). *P*-values \<0.05 were considered significant.

Results
=======

Population characteristics
--------------------------

The population demographics for the Guangzhou and Zhengzhou subjects were presented in our former publication.[@b30-cmar-10-1807]--[@b32-cmar-10-1807] The population demographics for the Wenzhou subjects are shown in [Table S1](#SD2-cmar-10-1807){ref-type="supplementary-material"}, while those of the combined subjects are shown in [Table S2](#SD3-cmar-10-1807){ref-type="supplementary-material"}. No statistically significant differences were observed between neuroblastoma cases and controls regarding age (*P*=0.229, *P*=0.484, *P*=0.496, *P*=0.119) and gender (*P*=0.510, *P*=0.196, *P*=1.000, *P*=0.840) for the Guangdong, Henan, Wenzhou, and combined subjects, respectively.

Correlation of MYCN gene polymorphisms with neuroblastoma susceptibility
------------------------------------------------------------------------

The genotype frequencies of *MYCN* gene polymorphisms and neuroblastoma susceptibility between all cases and controls for combined subjects and divided subjects are shown in [Tables 1](#t1-cmar-10-1807){ref-type="table"} and [S3](#SD4-cmar-10-1807){ref-type="supplementary-material"}, respectively. All of the 4 genotyped *MYCN* SNPs in controls conformed to the Hardy--Weinberg equilibrium for combined subjects (rs57961569 G\>A, *P*=0.379; rs9653226 T\>C, *P*=0.569; rs13034994 A\>G, *P*=0.907; and rs60226897 G\>A, *P*=0.526). In single genotype analysis, only 1 SNP rs57961569 G\>A was associated with neuroblastoma risk (GA vs GG: adjusted OR \[AOR)\] =0.76, 95% CI =0.60--0.98, *P*=0.033). No statistically significant associations were found between the other 3 SNPs (rs9653226 T\>C, rs13034994 A\>G, and rs60226897 G\>A) and neuroblastoma risk. We found that compared with subjects carrying 0--1 risk genotypes, subjects carrying 2--3 combined risk genotypes of *MYCN* exhibited enhanced risk of neuroblastoma, but this finding was nonsignificant (AOR =1.25; 95% CI =0.99--1.58).

Stratification analysis
-----------------------

Stratification analysis was further conducted to evaluate the effects of different strata (age, gender, tumor sites of origin, and clinical stages) on the association between the selected polymorphisms and neuroblastoma risk ([Table 2](#t2-cmar-10-1807){ref-type="table"}). Concerning the rs57961569 polymorphism, significant association was detected in the following subgroups: children older than 18 months (GG vs GA: AOR =1.38; 95% CI =1.01--1.88, *P*=0.040), tumor derived from the adrenal gland (GG vs GA: AOR =1.88; 95% CI =1.30--2.72, *P*=0.0008), and clinical stages III + IV (GG vs GA: AOR =1.40, 95% CI =1.02--1.92, *P*=0.037). The conferred increased neuroblastoma risk associated with the rs9653226 variant CC genotypes was more evident in the following subgroups: females (AOR =1.63, 95% CI =1.07--2.48, *P*=0.023), tumor derived from the adrenal gland (AOR =1.79, 95% CI =1.21--2.63, *P*=0.003), and clinical stages III + IV (AOR =1.63, 95% CI =1.15--2.31, *P*=0.006). In the stratified analysis of the cumulative effects of risk genotypes, we found that the presence of 2--3 risk genotypes had a significant relationship with the following subgroups: tumor derived from the adrenal gland (AOR =1.66, 95% CI =1.18--2.32, *P*=0.003) and clinical stages III + IV (AOR =1.35, 95% CI =1.004--1.81, *P*=0.047).

Discussion
==========

In the current study, we explored the impact of SNPs of the *MYCN* gene on the risk of neuroblastoma in the Chinese population. Our data revealed that the rs57961569 G\>A polymorphism in the *MYCN* gene presented significant inverse associations with neuroblastoma risk.

*MYCN* is located on chromosome 2p24.3 and encodes a pleiotropic nuclear phosphoprotein. The encoding protein consists of 2 domains: a carboxyterminal DNA-binding and protein interaction domain and an amino-terminal transcriptional activation domain. In healthy conditions in humans and mice, *MYCN* expression is high in certain tissues in the developing embryo, while it is low or even absent in adult tissues.[@b40-cmar-10-1807],[@b41-cmar-10-1807] Amplification of *MYCN* could promote proliferation and cell cycle progression. *MYCN* could also enhance neuroblastoma cell migration and invasion through downregulation of integrins α1 and β1.[@b42-cmar-10-1807],[@b43-cmar-10-1807] Moreover, *MYCN* modulates antigens on the surface of tumor cells, thus influencing immune surveillance.[@b44-cmar-10-1807] Brandetti et al[@b45-cmar-10-1807] demonstrated that *MYCN* functions as an immunosuppressive oncogene in neuroblastoma cells by negatively regulating the expression of ligands for DNAM-1and NKG2D NK-cell-activating receptors. Importantly, a study conducted by Dahlin et al[@b46-cmar-10-1807] was the first to investigate the relationship between *MYCN* gene variants and cancer risk. The study failed to establish a significant relationship between *MYCN* gene variant rs922 G\>A and medulloblastoma risk from 243 cases and 247 controls of Swedish and Danish children. The significance of *MYCN* in the initiation and development of cancer is self-evident.

Herein, we investigated for the first time whether *MYCN* gene SNPs could affect the risk of neuroblastoma in Chinese children. Among the 4 analyzed SNPs, only rs57961569 G\>A was associated with neuroblastoma risk. In the combined analysis, subjects carrying 2--3 risk genotypes tended to have increased neuroblastoma risk in comparison to those with 0--1 risk genotypes. This phenomenon was quite biologically plausible, as a single polymorphism in each gene may not be strong enough to influence the risk of cancer. Intriguingly, stratified analysis showed that individuals harboring the rs57961569 GG alleles were more likely to have a tumor in the following subgroups: children older than 18 months, tumor derived from the adrenal gland, and clinical stages III + IV. The contributing role of the rs9653226 CC genotype to increasing neuroblastoma risk was more evident in the females, tumor derived from the adrenal gland, and clinical stages III + IV subgroups. In the stratified analysis of the cumulative effects of risk genotypes, we found that the presence of 2--3 risk genotypes had a positive relationship with the following subgroups: tumor derived from the adrenal gland and clinical stages III + IV. On one hand, the same polymorphism might have a different role in cancer risk, depending on different ethnicities, regions, and cancer types. On the other hand, a conflicting role might also be the small sample size in the stratified analysis.

Several limitations accompany the merits of this study. First, the sample size was relatively small, although we gathered samples from 3 centers, especially for the stratification analysis. As a result, the strength of the statistical power may not be strong enough. Second, being a retrospective investigation, only genetic information in the *MYCN* gene was measured. Measuring other environmental factors, such as childhood exposure, dietary habits, and health situation, is critical in helping to further elucidate the role of *MYCN* polymorphisms in neuroblastoma risk. Third, only 4 SNPs in the *MYCN* gene were analyzed, so more polymorphisms in the *MYCN* gene should be investigated.

Overall, in the Chinese population studied, we provide the first evidence that polymorphisms in *MYCN* gene could influence neuroblastoma risk in a low-impact manner. Larger sample size studies with additional functional analysis are needed to better elucidate the role of *MYCN* polymorphisms in neuroblastoma risk.

Supplementary materials
=======================

###### 

Linkage disequilibrium analysis for the 4 selected polymorphisms in *MYCN* gene in Han Chinese population consisting of CHB (Han Chinese in Beijing, China) and CHS (Southern Han Chinese) subjects.

###### 

Frequency distribution of demographic characteristics for Wenzhou subjects

  Variables                 Cases (N=36)   Controls (N=72)   *P*-value[a](#tfn7-cmar-10-1807){ref-type="table-fn"}           
  ------------------------- -------------- ----------------- ------------------------------------------------------- ------- -------
  Age range, month          0.05--72                         8--72                                                           0.496
  Mean ± SD                 20.25±20.73                      23.58±15.36                                                     
   ≤18                      20             55.56             35                                                      48.61   
   \>18                     16             44.44             37                                                      51.39   
  Gender                                                                                                                     1.000
   Female                   17             47.22             34                                                      47.22   
   Male                     19             52.78             38                                                      52.78   
  Clinical stages                                                                                                            
   I                        15             41.67             --                                                      --      
   II                       2              5.56              --                                                      --      
   III                      9              25.00             --                                                      --      
   IV                       7              19.44             --                                                      --      
   4s                       3              8.33              --                                                      --      
  Sites of origin                                                                                                            
   Adrenal gland            11             30.56             --                                                      --      
   Retroperitoneal region   9              25.00             --                                                      --      
   Mediastinum              14             38.89             --                                                      --      
   Other regions            2              5.56              --                                                      --      

**Notes:**

Two-sided χ^2^ test for distributions between neuroblastoma patients and controls. "--" indicates no value.

###### 

Frequency distribution of demographic characteristics for combined subjects

  Variables                 Cases (N=429)   Controls (N=884)   *P*-value[a](#tfn8-cmar-10-1807){ref-type="table-fn"}           
  ------------------------- --------------- ------------------ ------------------------------------------------------- ------- -------
  Age range, month          0.00--132                          0.07--156                                                       0.119
  Mean ± SD                 34.61±27.49                        34.08±28.25                                                     
   ≤18                      146             34.03              340                                                     38.46   
   \>18                     283             65.97              544                                                     61.54   
  Gender                                                                                                                       0.840
   Female                   185             43.12              376                                                     42.53   
   Male                     244             56.88              508                                                     57.47   
  Clinical stages                                                                                                              
   I                        84              19.58              --                                                      --      
   II                       95              22.14              --                                                      --      
   III                      77              17.95              --                                                      --      
   IV                       150             34.97              --                                                      --      
   4s                       14              3.26               --                                                      --      
   NA                       9               2.10                                                                               
  Sites of origin                                                                                                              
   Adrenal gland            164             38.23              --                                                      --      
   Retroperitoneal region   96              22.38              --                                                      --      
   Mediastinum              123             28.67              --                                                      --      
   Other regions            38              8.86               --                                                      --      
   NA                       8               1.86                                                                               

**Notes:**

Two-sided χ^2^ test for distributions between neuroblastoma patients and controls. "--" indicates no value.

**Abbreviation:** NA, not available.

###### 

Genotype frequencies of *MYCN* gene polymorphisms and neuroblastoma susceptibility (divided subjects)

  Genotype                                                                         Guangdong province   Henan province   Wenzhou subjects                                                                                                                   
  -------------------------------------------------------------------------------- -------------------- ---------------- ------------------- ------- ------------- ------------- ------------------- ------- ------------ ------------ -------------------- -------
  rs57961569 G\>A                                                                                                                                                                                                                                           
   GG                                                                              124 (45.09)          230 (43.31)      1.00                        64 (54.24)    113 (40.21)   1.00                        14 (38.89)   29 (40.28)   1.00                 
   GA                                                                              114 (41.45)          243 (45.76)      0.87 (0.64--1.19)   0.371   42 (35.59)    135 (48.04)   0.54 (0.34--0.86)   0.009   15 (41.67)   34 (47.22)   0.93 (0.38--2.28)    0.877
   AA                                                                              37 (13.45)           58 (10.92)       1.19 (0.75--1.90)   0.459   12 (10.17)    33 (11.74)    0.64 (0.31--1.34)   0.237   7 (19.44)    9 (12.50)    1.61 (0.48--5.35)    0.439
   Additive                                                                                                              1.02 (0.82--1.26)   0.868                               0.69 (0.49--0.97)   0.032                             1.19 (0.66--2.14)    0.558
   Dominant                                                                        151 (54.91)          301 (56.69)      0.93 (0.69--1.25)   0.626   54 (45.76)    168 (59.79)   0.56 (0.36--0.86)   0.009   22 (61.11)   43 (59.72)   1.07 (0.46--2.47)    0.876
   Recessive                                                                       238 (86.55)          473 (89.06)      1.28 (0.82--1.99)   0.272   106 (89.83)   248 (88.26)   0.86 (0.43--1.74)   0.677   29 (80.56)   63 (87.50)   1.67 (0.56--5.01)    0.359
  rs9653226 T\>C                                                                                                                                                                                                                                            
   TT                                                                              93 (33.82)           181 (34.09)      1.00                        30 (25.42)    92 (32.74)    1.00                        15 (41.67)   20 (27.78)   1.00                 
   TC                                                                              124 (45.09)          262 (49.34)      0.91 (0.66--1.27)   0.584   62 (52.54)    141 (50.18)   1.34 (0.81--2.23)   0.261   16 (44.44)   36 (50.00)   0.57 (0.23--1.41)    0.225
   CC                                                                              58 (21.09)           88 (16.57)       1.29 (0.85--1.96)   0.228   26 (22.03)    48 (17.08)    1.61 (0.86--3.04)   0.140   5 (13.89)    16 (22.22)   0.40 (0.12--1.36)    0.142
   Additive                                                                                                              1.10 (0.90--1.36)   0.354                               1.28 (0.93--1.74)   0.129                             0.62 (0.34--1.12)    0.115
   Dominant                                                                        182 (66.18)          350 (65.91)      1.01 (0.74--1.37)   0.964   88 (74.58)    189 (67.26)   1.41 (0.87--2.29)   0.166   21 (58.33)   52 (72.22)   0.52 (0.22--1.22)    0.132
   Recessive                                                                       217 (78.91)          443 (83.43)      1.36 (0.94--1.97)   0.101   92 (77.97)    233 (82.92)   1.34 (0.78--2.29)   0.293   31 (86.11)   56 (77.78)   0.56 (0.19--1.68)    0.299
  rs13034994 A\>G                                                                                                                                                                                                                                           
   AA                                                                              166 (60.36)          300 (56.50)      1.00                        77 (65.25)    176 (62.63)   1.00                        22 (61.11)   50 (69.44)   1.00                 
   AG                                                                              90 (32.73)           202 (38.04)      0.80 (0.59--1.10)   0.171   32 (27.12)    89 (31.67)    0.84 (0.51--1.36)   0.472   12 (33.33)   20 (27.78)   1.41 (0.58--3.42)    0.444
   GG                                                                              19 (6.91)            29 (5.46)        1.18 (0.64--2.17)   0.602   9 (7.63)      16 (5.69)     1.37 (0.58--3.26)   0.476   2 (5.56)     2 (2.78)     2.39 (0.31--18.51)   0.404
   Additive                                                                                                              0.93 (0.73--1.19)   0.577                               1.01 (0.70--1.44)   0.974                             1.47 (0.72--3.00)    0.294
   Dominant                                                                        109 (39.64)          231 (43.50)      0.85 (0.63--1.14)   0.284   41 (34.75)    105 (37.37)   0.91 (0.58--1.44)   0.698   14 (38.89)   22 (30.56)   1.50 (0.64--3.50)    0.348
   Recessive                                                                       256 (93.09)          502 (94.54)      1.28 (0.70--2.33)   0.422   109 (92.37)   265 (94.31)   1.45 (0.6--3.41)    0.391   34 (94.44)   70 (97.22)   2.14 (0.28--16.16)   0.463
  rs60226897 G\>A                                                                                                                                                                                                                                           
   GG                                                                              130 (47.27)          262 (49.34)      1.00                        64 (54.24)    117 (41.64)   1.00                        14 (38.89)   31 (43.06)   1.00                 
   GA                                                                              116 (42.18)          215 (40.49)      1.09 (0.80--1.48)   0.600   43 (36.44)    130 (46.26)   0.59 (0.37--0.94)   0.028   15 (41.67)   33 (45.83)   1.05 (0.43--2.57)    0.919
   AA                                                                              29 (10.55)           54 (10.17)       1.09 (0.66--1.80)   0.727   11 (9.32)     34 (12.10)    0.60 (0.28--1.26)   0.176   7 (19.44)    8 (11.11)    1.98 (0.59--6.63)    0.270
   Additive                                                                                                              1.06 (0.85--1.32)   0.604                               0.70 (0.50--0.98)   0.037                             1.32 (0.74--2.38)    0.350
   Dominant                                                                        145 (52.73)          269 (50.66)      1.09 (0.81--1.46)   0.574   54 (45.76)    164 (58.36)   0.60 (0.39--0.92)   0.019   22 (61.11)   41 (56.94)   1.23 (0.53--2.85)    0.624
   Recessive                                                                       246 (89.45)          477 (89.83)      1.05 (0.65--1.70)   0.835   107 (90.68)   247 (87.90)   0.76 (0.37--1.56)   0.453   29 (80.56)   64 (88.89)   1.93 (0.63--5.87)    0.248
  Combined effect of risk genotypes[b](#tfn11-cmar-10-1807){ref-type="table-fn"}                                                                                                                                                                            
   0                                                                               131 (47.64)          239 (45.01)      1.00                        47 (39.83)    152 (54.09)   1.00                        21 (58.33)   37 (51.39)   1.00                 
   1                                                                               24 (8.73)            78 (14.69)       0.56 (0.34--0.93)   0.025   12 (10.17)    22 (7.83)     1.83 (0.84--3.99)   0.130   1 (2.78)     7 (9.72)     0.23 (0.03--2.07)    0.191
   2                                                                               53 (19.27)           111 (20.90)      0.86 (0.58--1.28)   0.458   26 (22.03)    49 (17.44)    1.79 (1.00--3.21)   0.049   8 (22.22)    13 (18.06)   1.10 (0.39--3.15)    0.859
   3                                                                               67 (24.36)           103 (19.40)      1.20 (0.82--1.74)   0.349   33 (27.97)    58 (20.64)    1.84 (1.07--3.16)   0.027   6 (16.67)    15 (20.83)   0.66 (0.22--2.02)    0.469
  Trend                                                                                                                  1.04 (0.92--1.17)   0.520                               1.24 (1.04--1.47)   0.014                             0.92 (0.66--1.29)    0.629
   0--1                                                                            155 (56.36)          317 (59.70)      1.00                        59 (50.00)    174 (61.92)   1.00                        22 (61.11)   44 (61.11)   1.00                 
   2--3                                                                            120 (43.64)          214 (40.30)      1.15 (0.85--1.54)   0.362   59 (50.00)    107 (38.08)   1.65 (1.07--2.55)   0.024   14 (38.89)   28 (38.89)   1.00 (0.43--2.31)    0.999

**Notes:**

Adjusted for age and gender.

Risk genotypes were rs57961569 GG, rs9653226 CC, rs13034994 GG, and rs60226897 GG.

**Abbreviations:** AOR, adjusted odds ratio; CI, confidence interval.
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###### 

Genotype frequencies of *MYCN* gene polymorphisms and neuroblastoma susceptibility

  Genotype                                                                        Cases (N=429)   Controls (N=884)   *P*-value[a](#tfn1-cmar-10-1807){ref-type="table-fn"}   Crude OR (95% CI)           *P*-value   AOR (95% CI)[b](#tfn2-cmar-10-1807){ref-type="table-fn"}   *P*-value[b](#tfn2-cmar-10-1807){ref-type="table-fn"}
  ------------------------------------------------------------------------------- --------------- ------------------ ------------------------------------------------------- --------------------------- ----------- ---------------------------------------------------------- -------------------------------------------------------
  rs57961569 G\> A (HWE =0.379)                                                                                                                                                                                                                                                 
   GG                                                                             202 (47.09)     372 (42.08)                                                                1.00                                    1.00                                                       
   GA                                                                             171 (39.86)     412 (46.61)                                                                **0.76 (0.60**--**0.98**)   **0.033**   **0.76 (0.60--0.98)**                                      **0.033**
   AA                                                                             56 (13.05)      100 (11.31)                                                                1.03 (0.71--1.49)           0.870       1.03 (0.71--1.50)                                          0.862
   Additive                                                                                                          0.069                                                   0.93 (0.78--1.11)           0.411       0.93 (0.78--1.11)                                          0.414
   Dominant                                                                       227 (52.91)     512 (57.92)        0.086                                                   0.82 (0.64--1.03)           0.087       0.82 (0.65--1.03)                                          0.087
   Recessive                                                                      373 (86.95)     784 (88.69)        0.360                                                   1.18 (0.83--1.67)           0.361       1.18 (0.83--1.67)                                          0.355
  rs9653226 T\>C (HWE =0.569)                                                                                                                                                                                                                                                   
   TT                                                                             138 (32.17)     293 (33.14)                                                                1.00                                    1.00                                                       
   TC                                                                             202 (47.09)     439 (49.66)                                                                0.98 (0.75--1.27)           0.862       0.98 (0.75--1.27)                                          0.850
   CC                                                                             89 (20.75)      152 (17.19)                                                                1.24 (0.89--1.73)           0.197       1.24 (0.89--1.73)                                          0.201
   Additive                                                                                                          0.292                                                   1.10 (0.93--1.29)           0.272       1.10 (0.93--1.29)                                          0.278
   Dominant                                                                       291 (67.83)     591 (66.86)        0.724                                                   1.05 (0.82--1.34)           0.724       1.04 (0.82--1.34)                                          0.736
   Recessive                                                                      340 (79.25)     732 (82.81)        0.119                                                   1.26 (0.94--1.69)           0.119       1.26 (0.94--1.69)                                          0.121
  rs13034994 A\>G (HWE =0.907)                                                                                                                                                                                                                                                  
   AA                                                                             265 (61.77)     526 (59.50)                                                                1.00                                    1.00                                                       
   AG                                                                             134 (31.24)     311 (35.18)                                                                0.86 (0.67--1.10)           0.221       0.86 (0.67--1.10)                                          0.225
   GG                                                                             30 (6.99)       47 (5.32)                                                                  1.27 (0.78--2.05)           0.335       1.27 (0.79--2.06)                                          0.329
   Additive                                                                                                          0.228                                                   0.98 (0.81--1.19)           0.868       0.99 (0.81--1.19)                                          0.878
   Dominant                                                                       164 (38.23)     358 (40.50)        0.431                                                   0.91 (0.72--1.15)           0.431       0.91 (0.72--1.15)                                          0.437
   Recessive                                                                      399 (93.01)     837 (94.68)        0.225                                                   1.34 (0.83--2.15)           0.227       1.34 (0.84--2.16)                                          0.222
  rs60226897 G\>A (HWE =0.526)                                                                                                                                                                                                                                                  
   GG                                                                             208 (48.48)     410 (46.38)                                                                1.00                                    1.00                                                       
   GA                                                                             174 (40.56)     378 (42.76)                                                                0.91 (0.71--1.16)           0.437       0.91 (0.71--1.16)                                          0.442
   AA                                                                             47 (10.96)      96 (10.86)                                                                 0.97 (0.66--1.42)           0.857       0.97 (0.66--1.43)                                          0.871
   Additive                                                                                                          0.738                                                   0.96 (0.80--1.14)           0.610       0.96 (0.81--1.14)                                          0.623
   Dominant                                                                       221 (51.52)     474 (53.62)        0.474                                                   0.92 (0.73--1.16)           0.474       0.92 (0.73--1.16)                                          0.482
   Recessive                                                                      382 (89.04)     788 (89.14)        0.958                                                   1.01 (0.70--1.46)           0.958       1.01 (0.70--1.47)                                          0.946
  Combined effect of risk genotypes[c](#tfn3-cmar-10-1807){ref-type="table-fn"}                                                                                                                                                                                                 
   0                                                                              199 (46.39)     428 (48.42)                                                                1.00                                    1.00                                                       
   1                                                                              37 (8.62)       107 (12.10)                                                                0.74 (0.49--1.12)           0.157       0.74 (0.49--1.12)                                          0.151
   2                                                                              87 (20.28)      173 (19.57)                                                                1.08 (0.80--1.47)           0.617       1.08 (0.80--1.47)                                          0.620
   3                                                                              106 (24.71)     176 (19.91)                                                                1.30 (0.97--1.74)           0.084       1.29 (0.96--1.74)                                          0.086
  Trend                                                                                                              0.086                                                   1.09 (0.99--1.19)           0.088       1.08 (0.99--1.19)                                          0.090
   0--1                                                                           236 (55.01)     535 (60.52)                                                                1.00                                    1.00                                                       
   2--3                                                                           193 (44.99)     349 (39.48)        0.057                                                   1.25 (0.99--1.58)           0.057       1.25 (0.99--1.58)                                          0.058

**Notes:**

χ^2^ test for genotype distributions between neuroblastoma patients and controls.

Adjusted for age and gender.

Risk genotypes were rs57961569 GG, rs9653226 CC, rs13034994 GG, and rs60226897 GG. Bold figures indicate 95% CI excluded 1 or *P*\<0.05.

**Abbreviations:** AOR, adjusted odds ratio; CI, confidence interval; HWE, Hardy--Weinberg equilibrium; OR, odds ratio.

###### 

Stratification analysis of risk genotypes with neuroblastoma susceptibility

  Variables          rs57961569 (cases/controls)   AOR (95% CI)   *P*-value[a](#tfn5-cmar-10-1807){ref-type="table-fn"}   rs9653226 (cases/controls)   AOR (95% CI)   *P*-value[a](#tfn5-cmar-10-1807){ref-type="table-fn"}   Combined                    AOR (95% CI)   *P*-value[a](#tfn5-cmar-10-1807){ref-type="table-fn"}                                          
  ------------------ ----------------------------- -------------- ------------------------------------------------------- ---------------------------- -------------- ------------------------------------------------------- --------------------------- -------------- ------------------------------------------------------- --------- ---------------------------- -----------
  Age, month                                                                                                                                                                                                                                                                                                                                                            
   ≤18               59/156                        67/149         1.19 (0.78--1.80)                                       0.419                        112/274        34/66                                                   1.25 (0.78--2.00)           0.347          80/200                                                  66/140    1.18 (0.80--1.74)            0.408
   \>18              112/256                       135/223        **1.38 (1.01**--**1.88)**                               **0.040**                    228/458        55/86                                                   1.29 (0.88--1.87)           0.189          156/335                                                 127/209   1.31 (0.98--1.75)            0.073
  Gender                                                                                                                                                                                                                                                                                                                                                                
   Female            72/181                        86/156         1.38 (0.94--2.02)                                       0.098                        136/308        49/68                                                   **1.63 (1.07**--**2.48)**   **0.023**      102/230                                                 83/146    1.28 (0.90--1.83)            0.172
   Male              99/231                        116/216        1.24 (0.90--1.73)                                       0.190                        204/424        40/84                                                   0.99 (0.66--1.50)           0.971          134/305                                                 110/203   1.23 (0.90--1.68)            0.189
  Sites of origin                                                                                                                                                                                                                                                                                                                                                       
   Adrenal gland     53/412                        89/372         **1.88 (1.30**--**2.72**)                               **0.0008**                   120/732        44/152                                                  **1.79 (1.21**--**2.64**)   **0.003**      79/535                                                  85/349    **1.66 (1.18**--**2.32**)    **0.003**
   Retroperitoneal   44/412                        41/372         1.02 (0.65--1.60)                                       0.936                        76/732         20/152                                                  1.27 (0.76--2.15)           0.365          56/535                                                  40/349    1.09 (0.71--1.67)            0.706
   Mediastinum       49/412                        55/372         1.25 (0.83--1.89)                                       0.281                        105/732        18/152                                                  0.82 (0.48--1.39)           0.455          70/535                                                  53/349    1.17 (0.80--1.71)            0.423
   Others            23/412                        11/372         0.53 (0.25--1.10)                                       0.086                        34/732         4/152                                                   0.57 (0.20--1.62)           0.291          29/535                                                  9/349     0.48 (0.22--1.02)            0.055
  Clinical stages                                                                                                                                                                                                                                                                                                                                                       
   I + II + 4s       76/412                        83/372         1.22 (0.87--1.71)                                       0.260                        152/732        27/152                                                  0.84 (0.54--1.32)           0.453          101/535                                                 78/349    1.19 (0.86--1.65)            0.292
   III + IV          88/412                        110/372        **1.40 (1.02**--**1.92**)                               **0.037**                    170/732        57/152                                                  **1.63 (1.15**--**2.31**)   **0.006**      121/535                                                 106/349   **1.35 (1.004**--**1.81**)   **0.047**

**Notes:**

Adjusted for age and gender. Bold figures indicate 95% CI excluded 1 or *P*\<0.05.

**Abbreviations:** AOR, adjusted odds ratio; CI, confidence interval.

[^1]: These authors contributed equally to this work
